Your session is about to expire
← Back to Search
STSA-1002 subcutaneous injection: dose 1 (First cohort) for Vasculitis
Study Summary
This trial studies the safety and effectiveness of a new drug in healthy people to see how it works and is tolerated.
- Vasculitis
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
Is the age cutoff for this research endeavor restricted to those aged 50 or under?
"Patients wishing to participate in this experiment must be aged between 21 and 57. For those younger, there are 6 other trails available while people 65 years or older can choose from 35 options."
Has the Federal Drug Administration sanctioned STSA-1002 subcutaneous injection: dose 1 (First cohort) for usage?
"As this is an early-stage Phase 1 trial, the safety of STSA-1002 subcutaneous injection: dose 1 (First cohort) has been assigned a score of one due to the limited amount of data available."
Are there any unfilled positions in this experiment for participants?
"Contrary to what is listed on clinicaltrials.gov, this study has ceased recruiting patients as of January 18th 2023. Nonetheless, there are still 38 other trials that require participants for their research and development initiatives."
Do I meet the necessary prerequisites for participating in this medical trial?
"This clinical trial is accepting 20 individuals, with ages ranging from 21 to 57 years old and currently suffering from antineutrophil cytoplasmic antibody associated vasculitis. Eligible participants must also have a healthy body mass index (21-31 kg/m2) that weighs in between 50-93 kilograms, agree to use highly effective contraceptive measures during the study and for 6 months after its completion; these include double barrier methods of contraception or hormonal contraceptives if they are females of non-childbearing potential who had been sterilized at least 6 months before screening - Follicle Stimulating Hormone levels should be ≥"
Share this study with friends
Copy Link
Messenger